Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How to explain the differences between renin angiotensin system modulators.

Bernard I Levy1

  • 1Center of Cardiovascular Research, INSERM Lariboisière, U689, 41 Boulevard de la Chapelle, 75010 Paris, France. levy@infobiogen.fr

American Journal of Hypertension
|August 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of sudden cardiac arrest during endurance racing: a decade of the Paris registry.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Are We Too Lenient Toward ARBs? A Balanced Appraisal in Light of New Multidatabase Evidence.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Michel Emile Safar 1937 to 2024.

Hypertension (Dallas, Tex. : 1979)·2024
Same author

Endothelin Receptor Blockade Improves Cerebral Blood Flow-Mediated Dilation in a Mouse Model of Alzheimer's Disease.

Journal of vascular research·2023
Same author

VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?

Hypertension (Dallas, Tex. : 1979)·2023
Same author

Corrigendum to: Renin Angiotensin Blockers and Cardiac Protection: From Basics to Clinical Trials.

American journal of hypertension·2022

Angiotensin II (Ang II) receptors, AT(1) and AT(2), have opposing roles in cardiovascular health. AT(1) activation promotes negative effects, while AT(2) may offer protective benefits, influencing neovascularization and tissue repair.

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Pharmacology

Background:

  • Angiotensin II (Ang II) is implicated in cardiovascular diseases like hypertension and cardiac hypertrophy.
  • Two Ang II receptor subtypes, AT(1) and AT(2), exist with distinct signaling pathways and functions.
  • While AT(1) roles are well-defined, the AT(2) receptor's function, particularly in adult human circulation, remains less understood.

Purpose of the Study:

  • To elucidate the differential roles of AT(1) and AT(2) receptors in cardiovascular physiology and pathology.
  • To investigate the involvement of AT(2) receptors in tissue remodeling, neovascularization, and potential therapeutic implications.
  • To re-evaluate the impact of renin-angiotensin system modulation on vascular protection.

Main Methods:

Related Experiment Videos

  • In vivo and in vitro investigations of Ang II receptor subtypes.
  • Analysis of receptor expression in fetal and adult tissues, including under conditions of injury.
  • Examination of the effects of AT(1) and AT(2) receptor activation on cellular processes like proliferation and apoptosis.
  • Assessment of the interplay between Ang II receptors, bradykinin, and hypoxia-induced neovascularization.

    • Main Results:

    • AT(1) receptor activation mediates vasoconstriction, hypertrophy, inflammation, and oxidative stress, contributing to cardiovascular disease progression.
    • AT(2) receptors, highly expressed in fetal life and re-expressed after injury, are suggested to play roles in tissue remodeling and development.
    • Experimental evidence indicates AT(1) activation is proangiogenic, while AT(2) activation is antiangiogenic (pro-apoptotic).
    • Bradykinin, via B(1)/B(2) receptors, promotes neovascularization, contrasting with AT(1) blockade effects.

    Conclusions:

    • Pharmacologic blockade of AT(1) receptors may impair neovascularization in ischemic tissues due to AT(2) overactivation.
    • Inhibition of the angiotensin-converting enzyme could enhance vascularization in ischemic tissues by increasing bradykinin.
    • These findings necessitate a reevaluation of vascular protection strategies involving different renin-angiotensin system modulators in clinical trials.